{"task_id": "3b400897c292733d", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 307/464)", "text": "r Science\u00feBusiness Media, LLC 2006, 2007, 2011\n297\n\n--- Page 319 ---\nCLINICAL FEATURES (CONT\u2019D)\nSIGNS\ncranial nerve examination, with particular\nattention to fundoscopy and visual fields (driving),\ncognitive assessment with MMSE (driving, should be\n\u000324), speech, motor, sensory, gait, cerebellum, pro\nnator drift, Romberg sign\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, lytes, urea, Cr, AST, ALT, ALP, bilir\nubin, INR, PTT, albumin\n\u0002\nIMAGING\nMRI head, CT head\n\u0002\nBIOPSY\nopen biopsy, stereotactic biopsy\nSPECIAL\n\u0002 MR SPECTROSCOPY\nN acetylaspartate, choline,\nlactate\n\u0002\nFUNCTIONAL MR\nblood flow\nPROGNOSTIC ISSUES\nPROGNOSIS FOR LOW GRADE GLIOMAS\nmedian\nsurvival 7 8 years, 5 year survival 64%; median time\nto recurrence 4.5 years, median survival from recur\nrence 12 months\nPROGNOSIS FOR GLIOBLASTOMA MULTIFORME\nmedian survival 14 weeks with observation only, 20\nweeks with resection, 36 weeks with radiation added,\nand 40 50 weeks with chemotherapy added\nPROGNOSTIC FACTORS FOR ANAPLASTIC ASTRO\nCYTOMA AND GLIOBLASTOMA MULTIFORME\nolder age, poor Karnofsky performance status, degree\nof excision, neurologic deficits\nMEDIANSURVIVALSFOROLIGODRENDROGLIOMAS\nOligodrendroglioma\n1p19q\ndeletion\nNo 1p19q\ndeletion\nLow grade\n15 years\n5 years\nHigh grade\n5 10 years\n2 years\nMANAGEMENT\nSYMPTOM CONTROL\nseizure control (phenytoin,\nlevetiracetam, carbamazepine, lamotrigine, cloba\nzam, valproate, topiramate), steroids may be used\nshort term for cerebral edema with symptoms such\nas headaches, neurological deficits\nTUMOR CONTROL\n\u0002\nASTROCYTOMA\n\u0002\nLOW GRADE (GRADE 2)\nmaximal surgical debulk\ning. Upfront radiation improves progressive free\nsurvival but not overall survival. Thus, it may be\ndelayed in patients who are asymptomatic\n\u0002\nANAPLASTIC\n(GRADE\n3)\nmaximal\nsurgical\ndebulking, followed by radiation \u0004 chemother\napy (PCV, temozolomide)\n\u0002\nGLIOBLASTOMA MULTIFORME (GRADE 4)\nmaximal\nsurgical debulking, concurrent chemoradiation\nwith temozolomide \u00056 weeks, followed by\nMANAGEMENT (CONT\u2019D)\n4 week break and then adjuvant temozolomide\nd1 5 q28d \u00056\n\u0002\nLOW-GRADE OLIGODENDROGLIOMA\n\u0002\nWITH 1P19Q DELETION\nresection. Chemother\napy at progression to delay radiation is an option\n\u0002\nWITHOUT 1P19Q DELETION\nresection. Radiation\nmay be delayed until progression or symptoms.\n\u0002\nHIGH-GRADE OLIGODENDROGLIOMA\n\u0002\nWITH\n1P19Q\nDELETION\nresection\n\u0004\nche\nmotherapy \u0004 radiation\n\u0002\nWITHOUT 1P19Q DELETION\nresection, RT alone\nor concurrent chemoradiation with temozolo\nmide \u00056 weeks, followed by 4 week break and\nthen adjuvant temozolomide d1 5 q28d \u00056\n\u0002\nSALVAGE\nCHEMOTHERAPY\nFOR\nGLIOMAS\nnitro\nsoureas, bevacizumab, etoposide, carboplatin,\nprocarbazine\n\u0002\nEPENDYMOMA\nresection \u0004 radiation. Palliative\nchemotherapy may be provided with recurrence\n\u0002\nPRIMARY NEUROECTODERMAL TUMORS (medullo\nblastoma,\nsupratentorial,\npineoblastoma)\nresection plus craniosoinal radiation for low\nrisk tumors may be curative. Add adjuvant che\nmotherapy (cisplatin, etoposide, cyclophospha\nmide or lomustine and vincristine) for high risk\ntumors\n\u0002\nMENINGIOMA\nobservation if asymptomatic and\nno mass effect. Otherwise, resection or radiation\nif surgery not possible\nDRIVING\nthe key factors that affect driving include\nseizures, visual fields, motor deficits, and cognition\n(MMSE \u0003 24)\nTREATMENT ISSUES\nSIDE EFFECTS OF BRAIN IRRADIATION\n\u0002\nRADIONECROSIS\ncontrast enhanced\nfocal\nlesion\nmay be difficult to differentiate from recurrent\nbrain tumor. Supportive measures\n\u0002\nRADIATION-INDUCED LEUKOENCEPHALOPATHY\noccurs\nmonths to years later. Symptoms may include gait\nataxia, urinary incontinence, and dementia\n\u0002\nRADIATION MYELOPATHY\nassociated with accumu\nlative radiation dose to the spinal cord, peaking at\n1 and 2 years. Symptoms may include Lhermitte\u2019s\nsign, paresthesias (pain and temperature) with\nprogressive loss of cord function over 6 months.\nSupportive measures only\nSPECIFIC ENTITIES\nHERNIATION SYNDROMES\n\u0002\nTRANSTENTORIAL\nsymmetric downward displace\nment of the hemispheres, causing impaction of\nthe diencephalon and midbrain into the tentorial\nnotch ! rostrocaudal deterioration with decorti\ncate evolving to decerebrate posturing\n298\nBrain Tumors", "text_length": 4075, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 307/464)", "type": "chunk", "chunk_index": 306, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.668729", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.669545", "status": "complete", "chunks_added": 3}